KCP
UTHR icon

Kera Capital Partners’s United Therapeutics UTHR Stock Holding History

Kera Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247K Sell
456
-15
-3% -$8.45K 0.02% 544
2026
Q1 		$279K Buy
471
+27
+6% +$13.4K 0.03% 438
2025
Q4 		$208K Buy
+444
New +$207K 0.03% 522

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Kera Capital Partners's UTHR Position: Q2 2026 in Review

Kera Capital Partners reduced its United Therapeutics (UTHR) stake by 3.2% in Q2 2026, selling an estimated $8.45K and leaving 456 shares worth $247K. The position accounts for 0.02% of the portfolio, ranked #544.

Kera Capital Partners first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $279K in Q1 2026. 883 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Kera Capital Partners held 456 shares of United Therapeutics worth $247K as of Q2 2026.
  • Kera Capital Partners sold 15 United Therapeutics shares in Q2 2026, an estimated $8.45K.
  • United Therapeutics made up 0.02% of Kera Capital Partners's portfolio in Q2 2026, its #544 holding.
  • Kera Capital Partners first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Kera Capital Partners's United Therapeutics position peaked at $279K in Q1 2026.
  • 883 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.